Abbott Laboratories

Abbott Reports 12-Month Positive Results From VOLT-AF IDE Study, Shares Rise 0.60%

雅培

Abbott Laboratories' 15-min chart shows MACD Death Cross, KDJ Death Cross.

Abbott Laboratories Director Starks Buys 4967 Shares at $109.14/Share on 2026-02-04.

Abbott Presents Positive Volt PFA System Results at AF Symposium

Goldman Sachs

5 Goldman Sachs Top Picks for High Dividend and Upside Potential

Catalyst<ul> <li>Most analysts rate ABT Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant with five bearish versus zero bullish indicators.</li> <li>Fund flow trends show negative overall movement with large and extra-large bucket outflows.</li></ul>

Key Factors

Abbott Laboratories' Volt Pulsed Field Ablation System demonstrated high success rates for AFib treatment over 12 months in clinical studies presented at the AF Symposium.Abbott's TactiFlex Duo Ablation Catheter showed safety and efficacy in reducing AFib episodes in complex cases, as reported in JACC: Clinical Electrophysiology.Director Daniel J. Starks of Abbott Laboratories purchased a total of 10,000 shares at prices of $109.14 and $108.33 per share on February 4, 2026.Abbott Laboratories is receiving payments related to Humira sales, following a settlement involving Stratagene and revenue rights for the drug.Abbott's Medical Devices segment has achieved double-digit organic growth for twelve consecutive quarters, highlighting its market leadership and innovation.

Recent Updates

ABT News